Richard Sue, MD
Pulmonary Disease · Gilbert, AZNPI 1053320168
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $172,244 of the $224,373 with a category attached, or 76.8%. Pulmonx Corporation accounts for 97.2% of it on its own, with 17 other manufacturers making up the rest. Reporting peaked in 2020 at $80,799 and has fallen 99.5% since, to $401 in 2025. Among pulmonary disease clinicians in AZ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 197 payments — averaging $1138.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pulmonx Corporation$218K
- Intuitive Surgical$2K
- CSA Medical, Inc$1K
- Genentech, Inc.$930
- Johnson & Johnson$917
- Boston Scientific$319
- plus $868 from 12 others
Across 35 payments — averaging $11,420 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Galvanize Therapeutics, Inc$320K
- GSK$45K
- Insmed, Inc.$30K
- Pulmonx Corporation$4K
What the payments were for
- Consulting fees$172,24477%
- Travel & lodging$45,91720%
- Food & beverage$5,8943%
- Education$3180%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pulmonx Corporation | 144 | $218,124 |
| Intuitive Surgical | 18 | $1,933 |
| CSA Medical, Inc | 1 | $1,282 |
| Genentech, Inc. | 1 | $930 |
| Johnson & Johnson(2 entities) | 9 | $917 |
| Boston Scientific | 4 | $319 |
| Galvanize Therapeutics, Inc | 2 | $195 |
| Noah Medical Corporation | 1 | $139 |
| Veran Medical Technologies, Inc. | 3 | $136 |
| Bayer | 1 | $95 |
| Olympus America Inc. | 4 | $79 |
| Actelion Pharmaceuticals US, Inc. | 2 | $63 |
| La Jolla Pharmaceutical Company | 1 | $46 |
| GSK | 2 | $37 |
| Vapotherm Inc | 1 | $28 |
| United Therapeutics Corporation | 1 | $23 |
| Imbio Inc. | 1 | $16 |
| Electromed, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Pulmonx Endobronchial Valve EBV$125,685
- ZEPHYR ENDOBRONCHIAL VALVE$90,660
- CHARTIS CATHETER$36,517
- ZEPHYR DELIVERY CATHETER$36,517
- PULMONX CHARTIS TABLET CONSOLE$36,517
- Da Vinci Surgical System$1,635
- MONARCH$448
- Monarch Platform$245
- GALAXY$139
How this compares
$224,373 in reported general payments places this provider in the 95th percentile of 250 pulmonary disease providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 19 | $13,596 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 21 | $10,527 |
| Fluconazole | 20 | $1,283 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta | $37 | $24,12440 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 250 pulmonary disease providers in Arizona.
Other pulmonary disease in Gilbert
- Harmeet GillGilbert$17K
- Amy BohanGilbert$17K
- Archan ShahGilbert$17K
- Thomas SlobigGilbert$16K
- Wahaj AhmedGilbert$15K
- George ParidesMesa$913K
- Rajat WaliaPhoenix$748K
- Abhinav MittalTucson$570K
- Brian PorvinPhoenix$276K
- Abid KhokarPhoenix$262K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.